Clinical Trial

Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 28, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.
Trial Details
NCT Number NCT06480630
Lead Sponsor Anhui Provincial Hospital
Conditions Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm
Enrollment 39 participants
Start Date 2024-07-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-06-28